Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.43 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 14/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29796700 | 0.88 | TGFBR1 (0.39) | KDRFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL23389890 | 0.88 | TGFBR1 (0.39) | KDRFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL29796469 | 0.88 | TGFBR1 (0.38) | KDRFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL23389880 | 0.88 | TGFBR1 (0.38) | KDRFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL23389975 | 0.85 | ABL1 (0.40) | KDRFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL28785431 | 0.84 | TGFBR1 (0.41) | KDRFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL30156362 | 0.84 | TGFBR1 (0.38) | KDRFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL25084993 | 0.84 | TGFBR1 (0.38) | KDRFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL29967757 | 0.79 | TGFBR1 (0.39) | KDRFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL25822670 | 0.79 | TGFBR1 (0.39) | KDRFGFR1FGFR2FGFR4FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210154179-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210154179-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | ALK, ACVR1, ACVR2A | KDR 86/4885FGFR1 123/4885FGFR2 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.